150 related articles for article (PubMed ID: 30686806)
1. Adjustment of Conditions for Combining Oxybutynin Transdermal Patch with Heparinoid Cream in Mice by Analyzing Blood Concentrations of Oxybutynin Hydrochloride.
Murakami Y; Sekijima H; Fujisawa Y; Ooi K
Biol Pharm Bull; 2019 Apr; 42(4):586-593. PubMed ID: 30686806
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous quantification of oxybutynin and its active metabolite N-desethyl oxybutynin in rat plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of oxybutynin transdermal patch.
Tian Y; Wen Y; Sun J; Zhao L; Xiong Z; Qin F
Biomed Chromatogr; 2019 Apr; 33(4):e4456. PubMed ID: 30536598
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
4. Topical Applications of a Heparinoid-Containing Product Attenuate Glucocorticoid-Induced Alterations in Epidermal Permeability Barrier in Mice.
Wen S; Wu J; Ye L; Yang B; Hu L; Man MQ
Skin Pharmacol Physiol; 2021; 34(2):86-93. PubMed ID: 33652434
[TBL] [Abstract][Full Text] [Related]
5. Investigation of molecular mobility of pressure-sensitive-adhesive in oxybutynin patch in vitro and in vivo: Effect of sorbitan monooleate on drug release and patch mechanical property.
Wang W; Liu C; Luo Z; Wan X; Fang L
Eur J Pharm Sci; 2018 Sep; 122():116-124. PubMed ID: 29928984
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
[TBL] [Abstract][Full Text] [Related]
8. Moisturizing lotions can increase transdermal absorption of the herbicide 2,4-dichlorophenoxacetic acid across hairless mouse skin.
Brand RM; Charron AR; Sandler VL; Jendrzejewski JL
Cutan Ocul Toxicol; 2007; 26(1):15-23. PubMed ID: 17464745
[TBL] [Abstract][Full Text] [Related]
9. New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin.
Nicoli S; Penna E; Padula C; Colombo P; Santi P
Int J Pharm; 2006 Nov; 325(1-2):2-7. PubMed ID: 16860952
[TBL] [Abstract][Full Text] [Related]
10. Objective evaluation of the efficacy of daily topical applications of cosmetics bases using the hairless mouse model of atopic dermatitis.
Matsumoto K; Mizukoshi K; Oyobikawa M; Ohshima H; Sakai Y; Tagami H
Skin Res Technol; 2005 Aug; 11(3):209-17. PubMed ID: 15998334
[TBL] [Abstract][Full Text] [Related]
11. Oxybutynin permeation in skin: the influence of drug and solvent activity.
Santos P; Watkinson AC; Hadgraft J; Lane ME
Int J Pharm; 2010 Jan; 384(1-2):67-72. PubMed ID: 19799975
[TBL] [Abstract][Full Text] [Related]
12. Formulation Development and Characterization of Nanoemulsion-Based Formulation for Topical Delivery of Heparinoid.
Bakshi P; Jiang Y; Nakata T; Akaki J; Matsuoka N; Banga AK
J Pharm Sci; 2018 Nov; 107(11):2883-2890. PubMed ID: 30055224
[TBL] [Abstract][Full Text] [Related]
13. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Oki T; Toma-Okura A; Yamada S
J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
[TBL] [Abstract][Full Text] [Related]
14. A topical heparinoid-containing product improves epidermal permeability barrier homeostasis in mice.
Yao Y; Guo P; Feng X; Shen C; Huang J; Zhang J; Elias PM; Hu L; Man MQ
Exp Dermatol; 2019 Aug; 28(8):956-960. PubMed ID: 31168829
[TBL] [Abstract][Full Text] [Related]
15. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
Ho C
Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
[TBL] [Abstract][Full Text] [Related]
16. Transdermal oxybutynin: for overactive bladder.
Bang LM; Easthope SE; Perry CM
Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
Yang Z; Teng Y; Wang H; Hou H
Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
[TBL] [Abstract][Full Text] [Related]
19. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
Merino Salas S
Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
[TBL] [Abstract][Full Text] [Related]
20. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
